No Detail Found!

Effectiveness of Levetiracetam as a First Line Anticonvulsant for Neonatal Seizures

Author(s)
Muhammad Hayat Khan Department of Neonatology, Pakistan Institute of Medical Sciences, Islamabad.Pakistan
Syeda Shireen Gul Department of Neonatology, Pakistan Institute of Medical Sciences, Islamabad.Pakistan
Qaiser Zaman Department of Neonatology, Pakistan Institute of Medical Sciences, Islamabad.Pakistan
Nadeem Ahmad Department of Neonatology, Pakistan Institute of Medical Sciences, Islamabad.Pakistan
Qurrat-ul-Ann Department of Neonatology, Pakistan Institute of Medical Sciences, Islamabad.Pakistan
Abstract
Objective: To determine the effectiveness of levetiracetam as a first line anticonvulsant in neonates presenting with seizures at a tertiary care hospital. Study Design: Prospective study. Place and Duration of Study: This study was conducted at the Department of Neonatology, Pakistan Institute of Medical Sciences (PIMS) Hospital, Islamabad from 23rd December, 2020 to 22nd June, 2021. Materials and Methods: One hundred and thirty eight neonates having clinical seizures with and without having documented EEG abnormality were enrolled. Levetiracetam as 50 mg/kg loading dose (diluted in 20 ml normal saline) was administered intravenously in 20 minutes, followed by a maintenance dose of 20 mg/kg intravenously every 12 hours. An additional 20 mg/kg loading dose of levetiracetam was administrated in case of persistent seizures despite initial levetiracetam load. Response to the levetiracetam was considered as the cessation of seizures clinically within a time frame of 30 minutes. Results: There were 79 (57.2%) males. Overall, mean age was 6.27±6.5 days. Mean birth weight was 2.33±0.64 kg. There were 80 (58.0%) neonates who belonged to urban areas of residence. There were 42 (30.4%) neonates who were born pre-term. Lower segment cesarean section was the commonest mode of delivery noted among 70 (50.7%) cases. Most frequent etiology of seizures was found to be sepsis 57 (41.3%) while hypoxic ischemic encephalopathy was reported in 49 (35.3%). Levetiracetam treatment was found to be successful in 122 (88.4%) neonates. No drug related serious adverse events were reported. Conclusion: Levetiracetam was found to be highly effective as a first line anticonvulsant in neonates presenting with seizures. No drug related serious adverse events were observed.
Publication Details
Page(s) 25-28
DOI DOI not available
Published Journal: Medical Forum, Volume: 32, Issue: 8, Year: 2021

Request the full text from PASTIC

Keywords
Levetiracetam, Neonate, Anticonvulsant, Seizures
0

Citations

0

Downloads

26

Views